ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against aTyr Pharma, Inc. for alleged violations of federal securities laws during the specified class period [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased aTyr securities between January 16, 2025, and September 12, 2025 [2]. - The Complaint alleges that aTyr's executives made materially false and misleading statements regarding the drug Efzofitimod, particularly about its efficacy and the ability for patients to taper steroid usage [3]. Group 2: Next Steps for Investors - Investors who suffered losses in aTyr have until December 8, 2025, to request to be appointed as lead plaintiff in the case [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful in the lawsuit [5]. - Bronstein, Gewirtz & Grossman, LLC is recognized for representing investors in securities fraud class actions and has recovered hundreds of millions for investors [6].